SPC472
Adagrasíb eða lyfjafræðilega viðunandi salt þar af
Status:
VeittApplication date:
11.6.2024Application published:
15.7.2024Grant published:
15.12.2025
Max expiry date:
8.1.2039Medicine name:
KrazatiMedicine for children:
No
Timeline
Today
11.6.2024Application
15.7.2024Publication
15.12.2025Registration
8.1.2039Expires
Marketing license
IS authorization number:
EU/1/23/1744Date:
12.1.2024
Foreign authorization number:
EU/1/23/1744Date:
5.1.2024
Owner
Name:
Mirati Therapeutics, Inc.Address:
Route 206 and Province Line Road, Princeton, New Jersey 08543 US
Name:
Array Biopharma Inc.Address:
3200 Walnut Street, Boulder, CO 80301 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3710439
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 22.11.2025